GLPwatch

Design, synthesis and biological evaluation of double fatty chain-modified glucagon-like peptide-1 conjugates.

Bioorg Med Chem · 2021

Last updated 2026-05-28

Researchers designed 12 versions of a GLP-1 drug with double fatty chains and tested them against semaglutide. Six versions showed stronger activation of the GLP-1 receptor than semaglutide, but three of those had slightly weaker effects on lowering blood sugar in living organisms. One version, called conjugate 2, had the highest receptor binding strength and was selected as a top candidate for further study.

AI summary of the abstract below.

JournalBioorg Med Chem, 2021
Citations8
Relative citation ratio0.43
NIH percentile26
Molecules
Conditions studied Type 2 Diabetes, Obesity

Abstract

Twelve double fatty chains and Aib-Arg-GLP-1 (7-37) were designed and obtained by microwave-assisted solid-phase synthesis. Then, twelve conjugates of Aib-Arg-GLP-1 (7-37) were synthesized in 1% triethylamine aqueous solution. Conjugates 2, 3, 6, 7, 10 and 11 showed better GLP-1 receptor activation potency than semaglutide. However, conjugates 2, 6 and 10 showed slightly worse glucose-lowering effects in vivo than semaglutide but better effects than conjugates 3, 7 and 11. The CD spectra of conjugates 2, 6 and 10 indicated that they had the same secondary structure as liraglutide and semaglutide. The receptor affinity results for conjugates 2, 6 and 10 measured by SPR (surface plasmon resonance) showed that conjugate 2 had higher receptor affinity than conjugates 6 and 10. In addition, albumin binding assays indicated that double fatty acid chains had obvious synergistic effects compared with single fatty acid chains. In conclusion, the structure-activity relationship of different side chains was summarized and one candidate, conjugate 2, was screened.

Verbatim abstract via PubMed 34216986 ↗